Fig 1.
Model schematic for CF-PSM [25].
CF-PSM, cystic fibrosis patient-level simulation model; IVA, ivacaftor; SC, standard care. Adapted from Rubin JL, et al. Ther Adv Respir Dis. 2019;13:1753466618820186.
Table 1.
Model inputs for disease progression and ivacaftor treatment efficacy [10, 13, 14, 35, 37–40].
Table 2.
Demographics and baseline characteristics for validation cohort from the Volkova studya [18].
Fig 2.
Comparison of observed and modeled 5-year mortality benefits of ivacaftor.
CrI, credible interval; IVA, ivacaftor; RR, relative risk; SC, standard care.